DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Chemotherapy Induced Nausea and Vomiting Understanding
    Chemotherapy Induced Nausea and Vomiting: Overview
    Chemotherapy Induced Nausea and Vomiting (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.

    "Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Nausea and Vomiting pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Nausea and Vomiting treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Nausea and Vomiting commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Nausea and Vomiting R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Nausea and Vomiting.

    Chemotherapy Induced Nausea and Vomiting Emerging Drugs Chapters
    This segment of the Chemotherapy Induced Nausea and Vomiting report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Chemotherapy Induced Nausea and Vomiting Emerging Drugs
    • APD403: Acacia Pharma
    APD403 is based on the selective dopamine antagonist amisulpride. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. The drug is currently in Phase II clinical studies for Chemotherapy-induced nausea and vomiting.
    • CAM2047: Camurus
    CAM2047 is along-acting subcutaneous granisetron depot for in development for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. It is currently under Phase I stage of development for the treatment of Chemotherapy-induced nausea and vomiting.
    Further product details are provided in the report??..

    Chemotherapy Induced Nausea and Vomiting: Therapeutic Assessment
    This segment of the report provides insights about the different Chemotherapy Induced Nausea and Vomiting drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Chemotherapy Induced Nausea and Vomiting
    There are approx. 15+ key companies which are developing the therapies for Chemotherapy Induced Nausea and Vomiting. The companies which have their Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage, i.e. phase II include, Acacia Pharma.
    • Phases
    DelveInsight’s report covers around 15+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • intravitreal
    • Subretinal
    • Topical
    • Molecule Type
    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Chemotherapy Induced Nausea and Vomiting: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Nausea and Vomiting therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Nausea and Vomiting drugs.

    Chemotherapy Induced Nausea and Vomiting Report Insights
    • Chemotherapy Induced Nausea and Vomiting Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Chemotherapy Induced Nausea and Vomiting Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Chemotherapy Induced Nausea and Vomiting drugs?
    • How many Chemotherapy Induced Nausea and Vomiting drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Nausea and Vomiting therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Chemotherapy Induced Nausea and Vomiting and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • Acacia Pharma
    • Camurus
    • LP Pharmaceuticals
    • Skye Bioscience
    • TALLC Corporation
    • Starton Therapeutics

    Key Products
    • APD403
    • CAM2047
    • Palonosetron buccal
    • Research program: cannabis-based therapeutics
    • TA-A002
    • Ondansetron transdermal